Presently, researchers use DNA sequencing as a method for identifying genetic variation. Scientists participating in an early evaluation of the technology are interested in studying the most widely recognized human genetic disorders, such as those caused by extra or missing chromosomes, as well as a broad spectrum of other disorders. Some of these data were presented at the European Society of Human Genetics meeting in Vienna, Austria.
3500 Dx Series Genetic Analyzers
This product are intended for use by trained operators in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility. This system will be distributed and used in specific European countries only, including France, Germany, Italy, the Netherlands, Spain, Sweden, and the UK. It represents the first CE system and accessories to comply with the European Union In Vitro Diagnostic Medical Devices Directive 98/79/EC. Commercial launch of the 3500 Dx Series Systems is expected in August 2009.
3500 Series Genetic Analyzers (For Research Use Only)
This product enables researchers to run up to 1,100 sequencing or 1,200 genotyping samples per day. It features novel consumable designs, incorporating the ability to track key information with radio frequency identification (RFID) tags, new optical and thermal systems designs, and redesigned data collection and analysis software, which enables easy generation of cost-effective analyses and high-quality data. The 3500 Series Systems are for research use only, and are expected to be commercially available in August 2009.
Dr. Emiliano Giardina, Professor of Medical Genetics, University of Rome “Tor Vergata”
“The 3500 Series of sequencers will support a wide variety of genetic research in Europe. This technology may also ease the analysis and create standardization for genetics laboratories, which will help alleviate the different quality of results that stem from varying technologies and chemistries.”
Dr. Roland Achmann, MVZ genteQ
“The results we obtained with the 3500 Series were of good quality and absolutely comparable with the data we receive with our current capillary electrophoresis platform. In addition to quality results, the new system also offers certain features that allow us to shorten the time to results, which is a very important advantage in our continuing effort to optimize our analysis workflow.”
Kip Miller, President of Life Technologies’ Genetic Systems Division
“The introduction of these two new lines of CE sequencing platforms further demonstrates Life Technologies’ commitment to innovation in DNA sequencing and our desire to broaden the applications of this technology. These highly automated and simplified solutions respond to the requirements of scientists and European clinicians for advanced genomic analysis technologies.”
